secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001178913-25-001394
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion partners with Catalent for siRNA formulation and manufacturing of SIL204
--------------------------------------------------------------------------------

- Collaboration with Catalent for SIL204 formulation development and clinical manufacturing at Limoges, France facility.
- SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic, colorectal, and lung cancers.
- Company plans to initiate human clinical trials for SIL204 in first half of 2026.
- Preclinical data showed significant reduction in primary tumor growth and metastatic spread in pancreatic cancer models.
- Regulatory submissions to Israel Ministry of Health expected H2 2025 and to EU in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/0001178913-25-001394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001394/zk2533046.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer